SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha ...

Looking for medication to treat folate-receptor-alpha-positive-epithelial-ovarian-cancer? Find a list of current medications, their possible side effects, dosage, and efficacy when used to treat ...

Treatment with Elahere (mirvetuximab soravtansine-gynx) showed consistent survival benefits in a long-term analysis from the phase 3 trial MIRASOL evaluating patients with folate receptor ...

Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This pipeline review ...

Source Reference: Matulonis UA, et al "Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from ...

Suggested remit: To appraise the clinical and cost effectiveness of mirvetuximab soravtansine within its marketing authorisation for treating folate receptor alpha-positive platinum-resistant advanced ...

"More that 90% of ovarian cancer overexpresses folate receptor alpha," he noted. Coleman presented the findings at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer.

FDA Approves Mirvetuximab Soravtansine for Folate Receptor Alpha–Positive Ovarian Cancer M. Alexander Otto, PA, MMS November 15, 2022 0 ...

--Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha to its Precise™ Oncology Solutions portfolio. "FRα, alongside ...